Beijing Increasepharm

Beijing Increasepharm Corporation Limited is a prominent Chinese pharmaceutical research and development institution founded in 1999, specializing in the modernization of Traditional Chinese Medicine (TCM) and the development of innovative drug formulations. The company operates an integrated business model that encompasses R&D design, pilot-scale production, and clinical research services through its network of eight subsidiaries, including Increasepharm (HK) Limited. Its research focus spans new TCM compound drugs, innovative delivery systems such as nanomedicines and aerosols, and consistency evaluations for generic drugs. Increasepharm maintains strategic academic collaborations with institutions like the Hong Kong Polytechnic University and Hong Kong Baptist University to advance treatments for osteoporosis, dementia, and ocular diseases. The company is recognized as a national high-tech enterprise and holds a leading position in the research of new TCM compound drugs and novel formulations in China.